Home › Compound Library › GLP-1 & Metabolic › Orforglipron
GLP-1 & Metabolic Research Preliminary

Orforglipron

Oral non-peptide small molecule GLP-1 receptor agonist. First-in-class daily pill format studied as an alternative to injectable GLP-1 therapies. Phase 3 trials underway (Eli Lilly).

GLP-1oralnon-peptidesmall moleculeweight lossdiabetesnovel
Half-life
~12–18 hours supporting once-daily oral dosing
SKUs Available
2
Evidence Level
Preliminary
Mechanism of Action

Small molecule allosteric GLP-1 receptor agonist. Binds transmembrane domain rather than extracellular domain used by peptide agonists. Full receptor activation without peptide backbone — first orally bioavailable GLP-1 RA compound.

Published Research Ranges & Study Context

Studies have administered: 3–36mg/day oral in phase 2 dose-ranging; 12mg and 36mg doses in phase 3

Important Research Framing These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings

Phase 2 (GZAR): 36mg dose achieved ~14.7% weight loss at 36 weeks. T2D phase 2: meaningful HbA1c reduction. Phase 3 outcomes pending. Potential to eliminate injection barrier for GLP-1 therapy.

Preliminary Primarily preclinical + case reports
Side Effects Observed in Research

GI: nausea, vomiting, diarrhea (similar to injectable GLP-1 class); generally dose-dependent onset

Available Configurations (SKU Reference)
ORF4 ORF8
Compounds Studied in Combination

These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.

Want a Complete Research Monograph?

Our AI can generate a 2,000+ word deep-dive on Orforglipron — including full clinical trial summaries, pharmacokinetics, and research frontiers.

Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.